A 68-year-old woman with a 15-year history of hypertension (on atenolol and hydrochlorothiazide) presents with progressive fatigue and nocturia ×3 for 3 months. She denies diabetes, proteinuria, or hematuria on prior screening. Current BP is 142/88 mmHg. Laboratory findings: serum creatinine 1.9 mg/dL (baseline 0.9 mg/dL 2 years ago), eGFR 32 mL/min/1.73m², serum sodium 138 mEq/L, serum potassium 4.2 mEq/L, serum bicarbonate 22 mEq/L, serum calcium 8.8 mg/dL, serum phosphate 3.8 mg/dL, serum albumin 3.9 g/dL. Urinalysis: specific gravity 1.010, no proteinuria, no RBCs. Renal ultrasound shows bilaterally small kidneys (8.5 cm each) with increased echogenicity. What is the most likely diagnosis?

Explanation

## Clinical Diagnosis This patient has **hypertensive nephrosclerosis** (chronic hypertensive kidney disease), a form of CKD secondary to long-standing, inadequately controlled hypertension. ## Key Diagnostic Features **High-Yield:** Hypertensive nephrosclerosis is the **second leading cause of CKD in developed countries** and the **leading cause in African Americans and hypertensive populations** [cite:Harrison 21e Ch 279]. ### Clinical Clues | Feature | Finding | Significance | |---------|---------|-------------| | **Duration of hypertension** | 15 years | Long-standing, chronic exposure to elevated BP | | **Baseline renal function** | Cr 0.9 → 1.9 mg/dL over 2 years | Gradual decline consistent with chronic process | | **Current BP control** | 142/88 (suboptimal) | Persistent hypertension accelerates nephrosclerosis | | **Proteinuria** | Absent | Hypertensive nephrosclerosis typically has **minimal or no proteinuria** (unlike diabetic or glomerular disease) | | **Kidney size on ultrasound** | Bilaterally small (8.5 cm) with increased echogenicity | Pathognomonic for chronic kidney disease; small kidneys indicate chronic fibrosis and atrophy | | **Urinalysis** | No RBCs, no casts | Rules out active glomerulonephritis | | **Electrolytes & minerals** | Normal K⁺, HCO₃⁻, Ca²⁺, PO₄ | No acute derangement; consistent with stable CKD Stage 3b | | **Serum albumin** | Normal (3.9 g/dL) | Rules out nephrotic syndrome | **Key Point:** The **absence of proteinuria** is a critical distinguishing feature. Hypertensive nephrosclerosis causes **tubulointerstitial fibrosis and vascular sclerosis** without significant glomerular damage, so proteinuria is minimal (<1 g/day) or absent. This contrasts sharply with diabetic nephropathy (heavy proteinuria) and IgA nephropathy (hematuria + proteinuria). ## Pathophysiology of Hypertensive Nephrosclerosis ```mermaid flowchart TD A[Chronic Hypertension]:::outcome --> B[Endothelial injury in afferent arteriole]:::action B --> C[Arteriolar sclerosis & medial hypertrophy]:::action C --> D[Reduced renal perfusion]:::action D --> E[Glomerular sclerosis & tubular atrophy]:::action E --> F[Interstitial fibrosis]:::action F --> G[Progressive GFR decline]:::outcome G --> H[Small, echogenic kidneys on ultrasound]:::outcome ``` **Clinical Pearl:** Hypertensive nephrosclerosis is a diagnosis of **exclusion** — it requires: 1. Long-standing hypertension 2. Progressive CKD 3. **Minimal or absent proteinuria** (≤1 g/day) 4. Small, echogenic kidneys on imaging 5. No evidence of other glomerular or systemic disease ## Why Not the Other Options | Option | Why Wrong | |--------|----------| | **Option 0: Acute tubular necrosis (ATN)** | ATN is an acute process with rapid Cr rise (hours to days), usually reversible. This patient has a 2-year gradual decline. No acute precipitant (sepsis, hypotension, nephrotoxin) is documented. ATN would show muddy brown casts on urinalysis (absent here). | | **Option 2: IgA nephropathy** | IgA is a primary glomerulonephritis that presents with **hematuria (often gross)** and **proteinuria**. This patient has neither. IgA typically affects younger patients (20–40 years) and progresses rapidly. Diagnosis requires renal biopsy showing IgA deposits on immunofluorescence. | | **Option 3: Chronic pyelonephritis with scarring** | Chronic pyelonephritis causes **focal renal scarring** (asymmetric kidney size) and is usually associated with **recurrent UTIs, fever, pyuria, or bacteriuria**. This patient has none of these. Ultrasound shows **bilateral, symmetric small kidneys** (global atrophy), not focal scars. | ## Management Implications **High-Yield:** Management focuses on **slowing CKD progression**: 1. **Tight BP control** — target <130/80 mmHg (KDIGO 2021) 2. **ACE-I or ARB** — first-line agents for renal protection; superior to beta-blockers or thiazides for slowing decline 3. **Avoid NSAIDs** — accelerate CKD progression 4. **Nephrology referral** — eGFR 32 warrants specialist co-management **Warning:** This patient is on **atenolol and hydrochlorothiazide** — neither is optimal for renal protection. ACE-I or ARB should be added or substituted.